FibroBiologics, Inc. (FBLG)
NASDAQ: FBLG · Real-Time Price · USD
2.250
+0.220 (10.84%)
Dec 20, 2024, 4:00 PM EST - Market closed
Company Description
FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company.
It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials.
It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.
FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.
FibroBiologics, Inc.
| Country | United States |
| Founded | 2021 |
| IPO Date | Jan 31, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 10 |
| CEO | Peter O’Heeron |
Contact Details
Address: 455 East Medical Center Boulevard, Suite 300 Houston, Texas 77598 United States | |
| Phone | 281 651 5150 |
| Website | fibrobiologics.com |
Stock Details
| Ticker Symbol | FBLG |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $30.00 |
| CIK Code | 0001958777 |
| ISIN Number | US31573L1052 |
| Employer ID | 86-3329066 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Peter O'Heeron | Founder, Chairperson and Chief Executive Officer |
| Robert E. Hoffman B.B.A., CPA | Interim Chief Financial Officer and Director |
| Dr. Hamid Khoja Ph.D. | Chief Scientific Officer |
| Ruben A. Garcia J.D. | General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 20, 2024 | 8-K | Current Report |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Oct 29, 2024 | 8-K | Current Report |
| Sep 24, 2024 | 8-K | Current Report |
| Aug 28, 2024 | 8-K | Current Report |
| Aug 27, 2024 | 8-K | Current Report |
| Aug 14, 2024 | EFFECT | Notice of Effectiveness |
| Aug 13, 2024 | POS AM | Post-Effective amendments for registration statement |
| Aug 7, 2024 | 10-Q | Quarterly Report |
| Jul 8, 2024 | ARS | Filing |